[{"data":1,"prerenderedAt":191},["ShallowReactive",2],{"drug-tizanidine":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":43,"contraindications":76,"warnings":96,"renal":97,"monitoring":98,"interactions":99,"review":100,"examples":103,"atc":109,"iran":111,"links":127,"populations":144,"usApproval":186},"tizanidine",1,{"fa":7,"en":8},"تیزانیدین","Tizanidine","musculoskeletal",{"fa":11,"en":12},"شل‌کننده عضلانی (آگونیست α2)","Muscle relaxant (alpha-2 agonist)",[14],{"name":15,"market":16},"Zanaflex","US",[18,19,7],"zanaflex","زانافلکس",[21,35],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"tab-2","tablet","oral","2 mg tablet (scored)",{"amount":27,"unit":28,"perUnit":23,"scored":29},2,"mg",true,[16],[32],{"source":33,"section":34},"fda-tizanidine","3",{"id":36,"form":23,"route":24,"label":37,"concentration":38,"markets":40,"refs":41},"tab-4","4 mg tablet (scored)",{"amount":39,"unit":28,"perUnit":23,"scored":29},4,[16],[42],{"source":33,"section":34},[44],{"id":45,"disease":45,"label":46,"population":49,"type":53,"unit":28,"dose":54,"refs":57,"limits":60,"notes":65},"spasticity",{"fa":47,"en":48},"اسپاستیسیتی — شروع ۲ mg هر ۶ تا ۸ ساعت در صورت نیاز (حداکثر ۳ نوبت)","Spasticity — start 2 mg every 6–8 h as needed (max 3 doses)",{"minAge":50},{"value":51,"unit":52},18,"year","fixed",{"perDose":27,"dosesPerDay":55,"intervalHours":56},3,8,[58],{"source":33,"section":59},"2.2",{"maxPerDay":61,"refs":62},36,[63],{"source":33,"section":64},"2",[66],{"text":67,"refs":70},{"fa":68,"en":69},"افزایش ۲ تا ۴ mg در هر دوز هر ۱ تا ۴ روز؛ حداکثر ۳۶ mg\u002Fday. آنزیم‌های کبدی در ابتدا و یک ماه بعد. قطع تدریجی ۲ تا ۴ mg در روز.","Increase by 2–4 mg per dose every 1–4 days; max 36 mg\u002Fday. Check liver enzymes at baseline and 1 month. Taper by 2–4 mg\u002Fday when stopping.",[71,72,74],{"source":33,"section":64},{"source":33,"section":73},"2.1",{"source":33,"section":75},"2.5",[77,86],{"id":78,"severity":79,"text":80,"refs":83},"ci","block",{"fa":81,"en":82},"همراه مهارکننده‌های قوی CYP1A2 (فلووکسامین، سیپروفلوکساسین)؛ حساسیت.","With strong CYP1A2 inhibitors (fluvoxamine, ciprofloxacin); hypersensitivity.",[84],{"source":33,"section":85},"4",{"id":87,"severity":79,"rule":88,"text":90,"refs":93},"child",{"maxAge":89},{"value":51,"unit":52},{"fa":91,"en":92},"در کودکان ثابت نشده.","Not established in children.",[94],{"source":33,"section":95},"8.4",[],[],[],[],{"status":101,"reviewer":102,"date":102},"unverified",null,[104],{"regimen":45,"formulation":22,"input":105,"expect":108},{"ageYears":106,"weightKg":107},40,70,{"perDose":27},[110],"M03BX02",{"status":112,"forms":113,"refs":122},"registered",[114,118],{"code":115,"en":116,"fa":117},"11500","TIZANIDINE 2MG TAB","قرص تیزانیدین ۲ میلی‌گرم",{"code":119,"en":120,"fa":121},"05635","TIZANIDINE 4MG TAB","قرص تیزانیدین ۴ میلی‌گرم",[123],{"source":124,"section":125,"url":126},"darooyab-generic","G-2800\u002FTizanidine","https:\u002F\u002Fwww.darooyab.ir\u002FG-2800\u002FTizanidine",[128,132,136,139,142],{"kind":129,"url":130,"label":131},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=076533","ANDA076533",{"kind":133,"url":134,"label":135},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=01c0d3d3-2373-a1b7-822a-80a66291a248","FDA Tizanidine",{"kind":137,"url":138,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa601121.html",{"kind":140,"url":141,"label":110},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=M03BX02",{"kind":143,"url":126,"label":8},"darooyab",{"pregnancy":145,"lactation":154,"pediatric":162,"geriatric":170,"reproductive":178},{"level":146,"text":147,"quote":150,"refs":151},"caution",{"fa":148,"en":149},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary There are no adequate data on the developmental risk associated with use of tizanidine tablets in pregnant women.",[152],{"source":33,"section":153},"8.1",{"level":146,"text":155,"quote":158,"refs":159},{"fa":156,"en":157},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There are no data on the presence of tizanidine in human milk, the effects on the breastfed infant, or the effects on human milk production.",[160],{"source":33,"section":161},"8.2",{"level":163,"text":164,"quote":167,"refs":168},"not-established",{"fa":165,"en":166},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","Safety and effectiveness in pediatric patients have not been established.",[169],{"source":33,"section":95},{"level":146,"text":171,"quote":174,"refs":175},{"fa":172,"en":173},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Monitor elderly patients because they may have an increased risk for adverse reactions associated with tizanidine tablets.",[176],{"source":33,"section":177},"8.5",{"level":146,"text":179,"quote":182,"refs":183},{"fa":180,"en":181},"برچسب نکته‌ای درباره بارداری، پیشگیری یا باروری زنان و مردان دارد.","Label has advice on pregnancy testing, contraception or fertility for females and males.","Oral administration of tizanidine to male and female rats resulted in adverse effects on fertility [see Nonclinical Toxicology (13.1) ].",[184],{"source":33,"section":185},"8.3",{"kind":187,"refs":188,"id":131},"ANDA",[189],{"source":33,"section":190},"SPL approval \u002F marketing category",1792191876112]